Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Cardiac metastases of Ewing sarcoma detected by 18F-FDG PET/CT.

Coccia P, Ruggiero A, Rufini V, Maurizi P, Attinà G, Marano R, Natale L, Leccisotti L, Calcagni ML, Riccardi R.

J Pediatr Hematol Oncol. 2012 Apr;34(3):236-8. doi: 10.1097/MPH.0b013e318242754d.

PMID:
22395217
2.

An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma.

Newman EN, Jones RL, Hawkins DS.

Pediatr Blood Cancer. 2013 Jul;60(7):1113-7. doi: 10.1002/pbc.24406. Epub 2012 Nov 28.

PMID:
23192939
3.

Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?

Ulaner GA, Magnan H, Healey JH, Weber WA, Meyers PA.

AJR Am J Roentgenol. 2014 Apr;202(4):859-67. doi: 10.2214/AJR.13.11239.

PMID:
24660717
4.

18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.

Gaston LL, Di Bella C, Slavin J, Hicks RJ, Choong PF.

Skeletal Radiol. 2011 Aug;40(8):1007-15. doi: 10.1007/s00256-011-1096-4. Epub 2011 Feb 6.

PMID:
21298431
5.

Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.

Arush MW, Israel O, Postovsky S, Militianu D, Meller I, Zaidman I, Sapir AE, Bar-Shalom R.

Pediatr Blood Cancer. 2007 Dec;49(7):901-5.

PMID:
17252575
6.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
7.
8.

Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours.

Györke T, Zajic T, Lange A, Schäfer O, Moser E, Makó E, Brink I.

Nucl Med Commun. 2006 Jan;27(1):17-24.

PMID:
16340719
9.

Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.

Völker T, Denecke T, Steffen I, Misch D, Schönberger S, Plotkin M, Ruf J, Furth C, Stöver B, Hautzel H, Henze G, Amthauer H.

J Clin Oncol. 2007 Dec 1;25(34):5435-41.

10.

The value of 18F-FDG-PET/CT imaging for sinonasal malignant melanoma.

Haerle SK, Soyka MB, Fischer DR, Murer K, Strobel K, Huber GF, Holzmann D.

Eur Arch Otorhinolaryngol. 2012 Jan;269(1):127-33. doi: 10.1007/s00405-011-1664-1. Epub 2011 Jun 29.

PMID:
21713453
11.

Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected].

Bestic JM, Peterson JJ, Bancroft LW.

Radiographics. 2009 Sep-Oct;29(5):1487-500. doi: 10.1148/rg.295095024. Review. Erratum in: Radiographics. 2010 Jan-Feb;30(1):301.

PMID:
19755607
12.
13.

Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.

Kresnik E, Mikosch P, Gallowitsch HJ, Kogler D, Wiesser S, Heinisch M, Unterweger O, Raunik W, Kumnig G, Gomez I, Grünbacher G, Lind P.

Eur J Nucl Med. 2001 Jul;28(7):816-21.

PMID:
11504077
14.

Utilization of positron emission tomography in the management of patients with sarcoma.

Benz MR, Tchekmedyian N, Eilber FC, Federman N, Czernin J, Tap WD.

Curr Opin Oncol. 2009 Jul;21(4):345-51. doi: 10.1097/CCO.0b013e32832c95e2. Review.

PMID:
19412096
15.

Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis.

Dietlein M, Krug B, Groth W, Smolarz K, Scheidhauer K, Psaras T, Stützer H, Lackner K, Schicha H.

Nucl Med Commun. 1999 Mar;20(3):255-61.

PMID:
10093075
16.

Extrarenal malignant rhabdoid tumor in childhood application of 18F-FDG PET/CT.

Howman-Giles R, McCowage G, Kellie S, Graf N.

J Pediatr Hematol Oncol. 2012 Jan;34(1):17-21. doi: 10.1097/MPH.0b013e31822541a6.

PMID:
22052165
17.

[The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].

Xu HF, Liu Y, Zhang JH, Zhou RS, Zhou FH, Yuan MH.

Zhonghua Jie He He Hu Xi Za Zhi. 2005 Feb;28(2):108-11. Chinese.

PMID:
15854393
19.

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.

J Clin Oncol. 2001 Jan 15;19(2):414-9.

PMID:
11208833
20.

[18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.

Hawkins DS, Schuetze SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad EU 3rd, Eary JF.

J Clin Oncol. 2005 Dec 1;23(34):8828-34.

Items per page

Supplemental Content

Write to the Help Desk